Spherix (SPEX) Reports Findings From New Study in Mice Showing SPX106T Yields Significant Reductions in Serum VLDL
6/27/2012 11:10:31 AM
BETHESDA, Md., June 27, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced that its drug candidate SPX106T reduced very low-density lipoprotein complexes (VLDLs) by 36% (p=0.05) in the blood of apolipoprotein E-deficient mice consuming a diet containing SPX106T, fat and cholesterol, compared with those consuming one containing sucrose, fat and cholesterol. These results support the findings from previous studies where SPX106T significantly reduced both VLDLs and low-density lipoprotein complexes (LDLs) in low-density lipoprotein receptor-deficient mice consuming a high carbohydrate diet (see http://www.spherix.com/documents/pr060211--SPX106.pdf).
comments powered by